Does the intensity of dissociation predict antidepressant effects 24 hours after infusion of racemic ketamine or esketamine in treatment-resistant depression? A secondary analysis from a randomized ...

SNRI combined with esketamine nasal spray is better at lowering clinical risks of treatment-resistant depression. Credit: pxhere.com ...

Spravato nasal spray, also known as esketamine, can now be used to treat depression in adults with treatment-resistant depression.

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid symptom relief.

Jan. 27, 2025 – After years of limited options, people with hard-to-treat depression finally have a new standalone treatment. The FDA’s latest approval of the nasal spray Spravato (esketamine ...

With an FDA nod on Tuesday, Johnson & Johnson ’s esketamine nasal spray Spravato became the industry’s first monotherapy approved for use in adults with treatment-resistant depression. The approval ...

Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD) with inadequate response to at least 2 oral antidepressants.

Meeting Coverage > Psych Congress Esketamine Also Effective Without Adjunctive Antidepressant — Trial data may expand use, with "opportunity to truly individualize treatment" ...

While both substances share a pharmacological lineage, their utilization in medical settings diverges, primarily due to the distinct molecular structure of esketamine, which is the S-enantiomer of ...